Actinium Pharmaceuticals Inc.

Actinium is a biopharmaceutical company developing cancer treatments using its alpha particle immunotherapy platform. Key product candidates include antibody-drug construct Actimab-A, comprising monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225, currently in multicenter Phase I/II clinical trials for the treatment of acute myeloid leukemia (AML), and Iomab-B, an antibody-drug construct comprising the BC8 monoclonal antibody and beta emitting radioisotope iodine 131, currently in preparation for a pivotal Phase III multicenter clinical trial for use in bone marrow conditioning for hematopoietic stem cells transplantation in relapsed and refractory AML patients. Founded in 2000, Actinium is headquartered in New York City.